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A B S T R A C T
Chronic fatigue syndrome (CFS) is known as a multi-systemic and complex illness, which induces fatigue and
long-term disability in educational, occupational, social, or personal activities. The diagnosis of this disease is
diﬃcult, due to lacking a proper and suited diagnostic laboratory test, besides to its multifaceted symptoms.
Numerous factors, including environmental and immunological issues, and a large spectrum of CFS symptoms,
have recently been reported. In this review, we focus on the nutritional intervention in CFS, discussing the many
immunological, environmental, and nutritional aspects currently investigated about this disease. Changes in
immunoglobulin levels, cytokine proﬁles and B- and T- cell phenotype and declined cytotoxicity of natural killer
cells, are commonly reported features of immune dysregulation in CFS. Also, some nutrient deﬁciencies (vitamin
C, vitamin B complex, sodium, magnesium, zinc, folic acid, L-carnitine, L-tryptophan, essential fatty acids, and
coenzyme Q10) appear to be important in the severity and exacerbation of CFS symptoms. This review highlights
a far-driven analysis of mineral and vitamin deﬁciencies among CFS patients.
1. Introduction
Chronic fatigue syndrome (CFS) is a distinctive syndrome char-
acterized by prolonged fatigue in combination with typical symptoms
such as muscle and joint pain, or headaches, tender lymph nodes, re-
current sore throat, signiﬁcant problems with cognition and con-
centration, memory, and sleep, and deterioration after physical activity
[1–10] (Fig. 1). The CFS diagnosis is given only in disease states with a
history of at least six months, and could only be identiﬁed after other
fatigue etiologies have been excluded [11]. The syndrome often results
in severe functional limitation. CFS may also be known as chronic fa-
tigue immune dysfunction syndrome, postviral fatigue syndrome,
myalgic encephalomyelitis (ME), or named by several other terms [12].
The prevalence of CFS varies from 0.4 to 2.5% in the general population
of the USA and the UK [13]. CFS has its highest impact in females,
rather than in males [14,15]. A possible reason is still far to be eluci-
dated, although CFS etiopathogenesis may have genetic and epigenetic
origins, [16] besides hormonal, viral and immune causes [17]. The
kinship with the wide cohort of autoimmune diseases might shed light
on the possible relationship between CFS and its higher frequency in
female subjects [7,18]. Estrogens and estrogen receptors, particularly
the ER-beta, are impaired and lowly expressed in subjects with CFS, a
circumstance that can be particularly exacerbated in female individuals
[19,20]. CFS prevalence is estimated to be 836,000 to 2.5 million in
American people in 2015, according to the Institute of Medicine (IOM),
although most of them have not been identiﬁed [21]. Many of CFS
patients show anxiety and depression disorders [22] with prevalence
rates of 42.2% and 33.3% respectively [23]. The social, cultural, an-
thropological and personal eﬀects of CFS are enormous on human
economy, and this condition is still poorly understood. The fatigue
symptoms may aggravate with mental or physical activity, but they do
not improve after resting periods. It has been demonstrated that CFS
might be the result of a mix of factors, such as viral infections (human
herpesvirus-6, mouse leukemia viruses, and Epstein-Barr virus (EBV),
intracellular bacteria, environmental factors, and immune system dis-
abilities, hormonal imbalances in the pituitary glands, adrenal glands,
or hypothalamus [7,24,25]. Herpesviruses have been longtime included
as a causal factor of CFS etiology [24,26]. Particularly concerning EBV,
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the pathogenesis of myalgic encephalomyelitis/chronic fatigue syn-
drome (ME/CFS) is caused by a viral infection, which elicits the for-
mation of ectopic lymphoid aggregates [27]. The viral etiopathogenesis
of CFS is a possible causative hypothesis, leading to immune disorders
[28]. However, the autoimmune tenet, by which CFS is ﬁnally eluci-
dated, is another hallmark in the pathway towards the comprehension
of the pathology. What is emerging from medicine, is that clinical CFS is
considered part of a spectrum of diseases including ﬁbromyalgia, irri-
table bowel syndrome and perhaps some further autoimmune diseases,
and thereby may be linked with autoimmune manifestations as well as
exposure to drugs or vaccines [29,30]. Further suggestions come from
investigating gut microbiota and its relationship with CFS [31]. A hy-
pothesis has been forwarded regarding the presence in the gut micro-
biome of CFS patients of D-lactate producing bacteria, such as occurring
in the D-lactate acidosis, for which synbiotics may be a possible treat-
ment [32,33]. Probiotics may be considered a therapeutic possibility for
CFS, as well as ﬁbromyalgia [9,34]. However, as the impairment in the
gut-brain axis includes microbiota, and intestinal immunity, several
immune-targeted treatments of CFS have also been taken into con-
sideration, such as B-cell clonal depletion and the use of humanized
antibodies [35–37].
Usually, CFS symptoms are associated with loss of memory, head-
aches, fatigue, enlarged and painful lymph nodes in the neck or armpits,
unrefreshing sleep, cognitive dysfunction, sore throat, unexplained
muscle or joint pain, and severe exhaustion over a 24-hour period after
mental or physical exercise [38,39]. Although there are signiﬁcant at-
tempts worldwide to elucidate the onset of CFS, no single etiology has
been reported for this syndrome. It is thought that a variety of causes
induces the development of CFS. Therefore, this review will try to
highlight the current evidence related to CFS pathogenesis as related to
nutrition, reliable biomarkers, nutritional interventions, as well as
possible treatments, to reveal potential nutritional interference. In ad-
dition, this review aims to present numerous aspects of the syndrome
that could be prone to successful intervention, such as fatigue or an
impaired immune response to metals and viral infections.
Fig. 1. The involvement of human body organs in chronic fatigue syndrome.
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2. A brief insight into the pathogenesis of chronic fatigue
syndrome
The etiology of CFS is unknown; however, observations suggest that
there may be at least two diﬀerent etiological subgroups. One subgroup
consists of patients with early, often undiagnosed Parkinson’s disease
[40] and may have further degenerative brain diseases [41], while the
other subgroup appears to be composed of patients with various low-
grade, but chronic infections or inﬂammations, including infections
with herpesvirus-6, Epstein-Barr virus and various enteroviruses
[42–46]. These infections could often be diagnosed serologically, when
looked for; yet, even in cases where no speciﬁc infectious agent has
been identiﬁed, it is likely to observe further signs strongly suggesting
chronic viral infection, such as high concentrations of protein kinase R
(PKR) [47], RNase L [47–49], 2–5 A synthetase [50] and elastase in
leukocytes [47], while at the same time RNase L inhibitor may be
downregulated. Furthermore, double-stranded RNA could induce the
RNase L inhibitor (RLI) [50]. The pathway of 2–5 A synthetase/RNase L
in patients with CFS shows to be deregulated (elastase and calpain in-
itiate 83 kDa RNase L proteolysis, generating two major fragments with
molecular masses of 37 and 30 kDa, respectively) and upregulated (i.e.
an increased activity of the RNase L enzyme and elevated levels of
bioactive 2–5 A synthetase) [51].
Moreover, the role of NK cells in CFS is of major importance [52].
During CFS, a dysregulation of protein kinase genes, causing NK cell
dysfunction with a marked reduction in the NK cytotoxic activity, was
observed [52,53]. The immunological landscape of CFS is particularly
complex [54]. A hypothesis about the NK-functional impairment in CFS
regards the activity of the Transient Receptor Potential Melastatin 3
(TRPM3) cation channels in NK cells, channels that showed a sig-
niﬁcant reduction in amplitude of the TRPM3 current after pregneno-
lone sulfate stimulation in isolated NK cells from CFS patients [55].
PKR is a component of the innate immunity antiviral pathway
[55,56]. It is activated upon binding to double-stranded RNA (dsRNA)
to undergo dimerization and autophosphorylation [56]. Its activations
in the bulk of cellular mechanisms, such as cellular and viral stress
responses, is modulated through the phosphorylation of the translation
initiation factor eIF2α [57]. PKR function needs some minimal re-
quirements such as autophosphorylation at the residue T446 in a ﬂex-
ible loop, named the activation loop, and homodimerization of its ki-
nase and RNA-binding domains [57]. Chronic activation of signaling
pathways associated with innate antiviral defense is likely to be central
in the pathogenesis of CFS, since many of the antiviral eﬀector mole-
cules (as well-known defense weapons), which are upregulated, are not
speciﬁc enough to attack only viral nucleic acids or protein, without
harming host cell macromolecules and functions (by inhibition of
synthesis or enhanced degradation of the host cell macromolecule), as
well.
While PKR activation in leukocytes in many patients with CFS must
be regarded as the evidence strongly suggestive of an infectious
etiology, some caution might, nevertheless, be warranted, since PKR
has also been reported to be activated by toxic oligomers of the
Alzheimer protein β-amyloid [54]. Therefore, PKR may play an im-
portant role in neurological disorders such as the Alzheimer’s disease,
even without any viral cause. However, simultaneous detection of in-
creased levels of pro-inﬂammatory cytokines, such as TNF-alpha and IL-
1, in patients [58,59] is indicative of an infectious or inﬂammatory
etiology. Increased neopterin levels in blood plasma also indicate an
ongoing inﬂammation [58,59].
3. Chronic fatigue syndrome and toxic metals
Studies have shown that delayed-type hypersensitivity (type 4 al-
lergy) to nickel (Ni) and Hg is more frequent in patients with CFS,
compared to healthy controls [60–62]. It has also been reported that
CFS patients' symptoms could be improved after the removal of dental
amalgam [63–65]. Past reports from Stejskal et al. investigated the role
of dental amalgam removal in 111 patients with symptoms resembling
CFS and metal hypersensitivity [63]. MELISA, the optimized lympho-
cyte transformation test, was used to test for the presence of metal al-
lergy. When comparing 116 healthy subjects, a CSF-like syndrome has
been reported, using metal-speciﬁc lymphocytes in the blood of a sig-
niﬁcant number of patients [63,64]. Nickel was reported as one of the
most frequent sensitizers, followed by inorganic Hg, Ag, phenyl mer-
cury, cadmium (Cd), and palladium (Pd) [64]. The reactivity of lym-
phocytes to metals declined after dental metal removal, and 83 patients
(76%) showed long-term health improvement, 24 patients (22%)
showed unchanged health and two of them (2%) showed worsening of
symptoms [64]. Although metal-induced inﬂammation is involved in
the pathogenesis of CFS, important observations are suggesting that
chronic viral infections may be an important part of the etiopatho-
genesis at least in a large subgroup of patients [46,65–67]. Presumably,
the many factors that may contribute to suppression of the parts of the
immune system that are important for ﬁghting viruses will enhance the
risk of chronic or long-lasting infection, resulting in the development of
CFS. Potentially important contributory mechanisms in CFS, may be the
reduced leukocyte growth rates and the reduced expression of high-
aﬃnity and/or intermediate-aﬃnity receptors for interleukin-2 (IL-2)
on leukocytes, resulting from poor functional Se status [66,68,69], due
to the combined eﬀect of suboptimal Se intake and a high total content
of Se-antagonistic toxic metals [70,71]. Enhanced expression of the
immunosuppressive cytokine TGF-β may result from toxic metal ex-
posure, because of the induction by the lipid peroxidation product 4-
hydroxynonenal [72], an induction which is also triggered by poor Se
status [73,74].
4. Nutrition and nutraceutical supplementation. Insights into the
role of selenium in the chronic fatigue syndrome
Sub-optimal Se intake or poor functional Se status, due to too much
Se-antagonistic toxic metals, is expected to lead to an enhanced
synthesis of prostaglandin E2 (PGE2) [75]. Oxidative activation of sig-
naling pathways causing enhanced expression of cyclooxygenase-2
(COX-2) in individuals with poor Se status and a high ratio of omega-6
to omega-3 polyunsaturated fatty acids (PUFAs) in the diet, will also
cause an increased prostaglandin synthesis [75,76]. For example, the
prostaglandin PGE2 is an important suppressor of leukocyte types that
are important for ﬁghting viral infections. At the same time, PGE2 is one
of the important signal substances, skewing the phenotype of macro-
phages from being antiviral and antitumor soldiers to become im-
munosuppressive M2 macrophages [77]. This is an important snowball
eﬀect of deﬁcient Se status and high intake of omega-6 PUFAs since
PGE2 increases the expression of non-protective enzymes in leukocytes
[78–80].
5. Bacterial and viral co-infections in CFS as a leading cause of
microbiota impairment
It is a plausible working hypothesis that CFS may be a disease
perpetuating itself because of a number of interlocking vicious circles,
leading to immunosuppression, due to the deleterious eﬀect of infection
per se or other chronic inﬂammatory conditions [81–83]. Gut micro-
biota is expected to exert a leading role in this sense [84]. The resulting
inﬂammatory reactions may be self-perpetuating, which causes en-
hancement of oxidative and nitrative stress [2,59], as well as enhanced
degradation of several nutrients. In turn, this can lead to persistence of
various infections at a moderate level of activity, which is not acutely
life-threatening but can lead to very remarkable impairment of the
patient’s quality of life. If this hypothesis is correct, treatment should be
directed at trying to break as many as possible of the vicious circles
concerned through a multifactorial intervention.
In the gastrointestinal tract, it is conceivable that inhibition of a
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nucleolar protein might cause inhibition of the growth of enterocyte
and colonocyte progenitor cells, as well as various forms of disturbance
of immunological functions, which may play a role not only in chronic
infections but also in allergic and autoimmune disorders [85]. More-
over, it is also conceivable that inhibition of nucleolar function might
cause reduced production of various secreted proteins that are needed
for the normal function of the gastrointestinal tract, and perhaps en-
hanced leakiness of the mucosal epithelium. Also, it has been revealed
that chronic infections are the most common feature of illness in CFS
patients [85]. Numerous studies in American and European CFS pa-
tients reported that the most common of bacterial infections are due to
mycoplasma [85,86]. For example, a study of 261 CFS patients showed
that 68.6% of Belgian patients have one or more species of mycoplasma
in their blood [87]. Furthermore, it has been reported that North
American CFS patients had M. hominidis as the most common species,
revealing the diﬀerences in exposures and demography between Bel-
gian and North American CFS patients. Another study with 200 CFS
patients conﬁrmed a high prevalence (overall 52%) of mycoplasma
infections, along with Chlamydia pneumoniae and human herpesvirus‐6
[86,88]. Also, CFS patients show evidence of Brucella spp. [86,89,90].
Certain types of infections in CFS patients are also commonly reported
as human herpesvirus‐6 (HHV-6), mouse leukemia viruses and Epstein-
Barr virus, Chlamydia, and Borrelia species [88].
6. Nutrition byproducts. Chronic fatigue syndrome and oxidative
stress
Many CFS patients show nitrosative and oxidative stress, and a
chronically activated innate immune system [2,91]. Recent studies
have demonstrated that the generation of free radicals could be in-
volved in CFS etiology [1,3,91]. Fatigue symptoms could be related to
the loss in the eﬀectiveness of the electron transport chain and declined
mitochondrial function. Oxidative mitochondrial damage, particularly
from Reactive Oxygen Species (ROS), induces damage to mitochondrial
membrane lipids, which results in rapid loss of mitochondrial function,
although it causes the peroxidation of proteins and DNA as well as the
cellular mitochondrial lipids [92]. In other words, because of the for-
mation of excess free radicals, oxidative stress could be involved in the
CFS pathology, as well as being associated with symptomatic pre-
sentation [93]. Chronically activated immune-inﬂammatory responses
and nitrosative and oxidative stress in CFS patients, induce brain dis-
orders such as brain hypoperfusion/hypometabolism, neuroinﬂamma-
tion, DNA damage, mitochondrial dysfunctions, secondary autoimmune
responses directed against disrupted proteins and lipid membrane
components, and dysfunctional intracellular signaling pathways
[2,3,93]. Furthermore, Morris and his colleagues reported that hypo-
function of the hypothalamic-pituitary-adrenal axis in CFS patients is
known as a consequence of nitrosative and oxidative pathways, and
stimulated immune-inﬂammatory responses [1]. The explanations of
this mechanism could be attributed to the elevated levels of tumor
necrosis factor-α, increased levels of nitric oxide, regulatory T cell re-
sponses with increased levels of transforming growth factor-β and in-
terleukin-10, and viral/bacterial-mediated pathways [1]. Oxidative
stress and energy metabolism have been elucidated as a dysfunction in
the metabolic pathways of CFS patients [94]. Moreover, the response of
CFS patients to accumulative exercise is related with accentuated oxi-
dative stress, as well as with noticeable changes in the muscle mem-
brane dysfunction that induce post-exercise malaise and muscle pain
reported by CFS patients [95,96]. Finally, IgM-associated immune re-
sponses, directed against disrupted lipid membrane components and
proteins, could be induced by nitrosative or oxidative stress in CFS
patients [97].
7. Chronic fatigue syndrome and reliable biomarkers in the
nutrition therapy
Anti-oxidative and pro-oxidant stress activity could be applied as
markers for CFS patients [11,98]. Moreover, the 8-iso-prostaglandin-
F2α-isoprostane contents could be used as a plasma biomarker of nu-
trient-derived oxidative stress in CFS patients [99]. A signiﬁcant de-
crease in the cytotoxic activity of natural killer (NK) cells, as detailed in
the introduction, is a persistent ﬁnding in CFS patients compared with
healthy controls [100,101]. Furthermore, a notable increase in
CD19+IgM+ B cells and CD20+CD5+ B cells has also been described in
CFS [102]. Another study reported that elevated CD38 and human
leukocyte antigen (HLA)-DR expression on CD8+ T cells could be used
as markers of CFS [103]. The relevance of biomarkers with health-re-
lated quality of life and history of stressors in CFS patients revealed that
severe changes of the redox status, muscle excitability, and the level of
CD26-expression, are related to an important impairment of the quality-
of-life [104]. Microarray analysis of 34 microRNAs in the peripheral
blood mononuclear cells (PBMC) from CFS patients showed that hsa-
miR-99b, hsa-miR-126, hsa-miR-330, and hsa-miR-30c are potential
diagnostic biomarkers in NK cells of CFS patients [105]. All four bio-
markers may diﬀerentiate CFS patients from healthy controls and
suggests a changed activation of the NK cell pathway in CFS, for the
decreased eﬀector function seen in CFS. On the other hand, activin B,
which is a protein member of the Transforming Growth Factor-β (TGF-
β) family, is reported as a new biomarker for CFS patients. The eva-
luation of the activin levels and follistatin levels will be useful in se-
parating CFS from other fatigue-related disorders [106].
8. Chronic fatigue syndrome and nutritional intervention
The cellular energy systems of mitochondria appear to contribute to
the complex pattern of symptoms in CFS. It has been reported that
cellular mitochondrial damage can spoil the cell's abilities to produce
high-energy molecules, including NADH and ATP. This occurs naturally
during chronic illness, mainly because of damaged mitochondrial
components with impaired function [92]. Over the last years, there has
been a signiﬁcant increase in the quality of evidence-based nutritional
intervention for CFS. A brief summary of the suggested nutritional in-
terventions in CFS is summarized in Table 1.
Numerous reviews reported that some nutritional deﬁciencies could
be involved as etiologic agents for CFS. These include deﬁciencies of
vitamin C, vitamin B complex, sodium, magnesium, zinc, folic acid, L-
carnitine, L-tryptophan, essential fatty acids, and coenzyme Q10 [107].
For example, a dose-response association and long-lasting eﬀects of
B12/folic acid provide a proper positive reaction in the examined CFS
patients [108]. The low content of serum vitamin E during the remis-
sion and exacerbation phase of CFS patients revealed that high oxida-
tive stress could be contributing to the CFS pathogenesis, and may be
directly related to the severity of the symptoms of CFS patients, in-
dicating that antioxidant supplementation could alleviate muscle
symptoms in this syndrome [109]. Moreover, Maric and his colleagues
revealed that multivitamin-mineral supplements could be a safe and
Table 1
Nutritional supplements suggested in chronic fatigue syndrome; an alternative
recommendation can be found in reference [117].
Nutrient Dose Number of
Patients
Reference
Vitamin B12 1–10mg/week (IM) 38 [108]
Folic acid 1–5mg/day (oral) 38 [108]
Supradyn® 1/day (oral) 38 [110]
NADH+coenzyme Q10 20mg/day+ 200mg/day
(oral)
73 [89]
D-ribose 3× 5mg/day 41 [116]
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easy approach to alleviate the CFS symptoms and improve quality of
life [110].
Adequate lipid replacement and antioxidant therapy as nutritional
supplements, could control oxidative membrane damage and restore
cellular membrane and mitochondrial functions, through the delivery
of undamaged lipids and antioxidants to oxidized lipids of cellular or-
ganelles, to remove damaged lipids by lipid replacement [111]. Recent
clinical trials using CFS patients have reported the beneﬁt of anti-
oxidants and lipids to reduce moderate to severe CFS symptoms. An-
other study showed that a combination of glycophospholipid-anti-
oxidant-vitamin signiﬁcantly decreases the symptoms of fatigue within
one week [112]. Overall, the various forms of nutritional intervention
highlight mixed outcomes in terms of eﬃcacy.
All results concerning eﬃcacy might be evaluated along with the
inadequate approaches in studies. Nutritional interventions have re-
ported potential results regarding graded exercise therapy and beha-
vioral therapy. Further evaluation of nutritional treatment is hotly de-
manded through approaches to obtain standardized results.
9. Clinical evidence
Numerous clinical studies concerning CFS have been published, but
drawing ﬁnal conclusions is extremely diﬃcult, due to the diverse
nature of the syndrome. The lack of a straightforward deﬁnition, as well
as of clear-cut criteria, makes it diﬃcult to compare studies. In result,
there exists signiﬁcant overlap with other diseases, causing an im-
portant bias in many clinical trials. Moreover, nutritional intervention
has only recently come to be appreciated as part of a therapeutic ap-
proach, limiting the amount of evidence. Most existing trials are ob-
servational, and those that are interventional, do not always display
high quality, with the number of actual RCT's, although the gold
standard, being rather limited. Another problem is the nature of using
nutritional supplementation, which can be centered around a single
nutrient, but also in the form of combinations in a cocktail, making
analysis and drawing conclusions diﬃcult. Nevertheless, some rather
interesting trends, also from systematic reviews with or without meta-
analysis, can be observed at this time.
A study examining alternative treatments, found some hints towards
a positive eﬀect on CFS, making use of magnesium, L-carnitine, and S-
adenosylmethionine as supplements in CFS patients [113]. However, it
should be highlighted that most trials are of poor quality, using dif-
ferent methods (including a dosage of nutrients), lacking documenta-
tion of dietary intake, showing only a short follow-up, examining only a
small number of patients, using a heterogeneous population, and
lacking sound clinical endpoints. Despite these shortcomings, the ma-
jority of trials examined, showed positive results, warranting con-
ﬁrmatory trials.
A more recent evaluation could not demonstrate an eﬀect on CFS
outcome, but most trials did have an eﬀect on symptoms, typically fa-
tigue, using nicotinamide adenine dinucleotide hydride (NADH), pro-
biotics, chocolate, and coenzyme Q10 [114]. As nutritional trials are
diﬃcult to perform properly, overall quality remains poor, owing to the
same problems encountered as mentioned above. Again, nutritional
supplements are hinted to alleviate at least some of the problems en-
countered with CFS.
Eventually, a meta-analysis was recently performed, not able to
conﬁrm that vitamin and mineral deﬁciencies altogether play a major
role in CFS, but with some doubt remaining on vitamin E deﬁciency
[115]. This analysis also could not ﬁnd any beneﬁt from nutritional
intervention, although only a very limited number of interventional
trials were examined here.
Finally, another systematic review suggested a positive eﬀect of
nutritional supplements again, such as D-ribose, albeit only on symp-
toms, with special regard to supplementation of omega-3 fatty acids,
whose blood levels could also be linked to relief of symptoms [116].
Again, all the previously mentioned shortcomings continue to exist, and
no ﬁnal conclusion can be drawn at this point.
10. Conclusion
Despite the huge amount of hypotheses, the most frequent sugges-
tion is that an infectious etiology should be regarded as being plausible
for the etiology of CFS. However, possible further causes related to the
gut/brain axis and the microbiota-related immune disorders, including
autoimmunity, are possible suggestions. The numerous investigated
classiﬁcations of CFS patients, with regard to symptomatic patterns and
severity, could be useful to anticipate eﬀectiveness or therapeutic
prognosis. Many insights are to be elucidated, anyway. A meta-analysis
with 27 studies concludes that there are still few data to provide a
promising hypothesis for the eﬀective role of mineral and vitamin
supplementation in the CFS pathophysiology and therapy. Current
studies on minerals and vitamins in CFS patients need large population-
based and age-matched prospective research, as well as well-observed
interventional studies in CFS patients, to achieve more awareness in the
eﬃcacy of minerals and vitamins in the CFS pathophysiology.
According to this analysis, vitamin A and vitamin E are promising vi-
tamins that need further examination.
Further analysis of CFS patients can be earned by applying diag-
nostic criteria according to systematic evaluation. In addition, future
investigations need to evaluate whether phenotypes of CFS predict the
outcome of treatment. On the other hand, anxiety and depression of
CFS patients warrant further studies to explore a better vision of how
these features could inﬂuence symptomatic and interventional man-
agement.
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